EuroBiotech: More Articles of Note


> 4SC licensed Kv1.3 inhibitors to Maruho. The deal could net 4SC more than €200 million ($230 million) in milestones if Maruho turns the preclinical compound class into a commercial product. Statement

> One Nucleus named Toby Jones as its chief executive. The Cambridge, U.K.-based life science membership organization is promoting Jones to replace outgoing leader Harriet Fear. Release

> Targovax sold about 320,000 of the 2 million shares it offered. Statement

Sponsored By Syneos Health

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

> Can-Fite took a step toward enrolling patients in its phase 2 non-alcoholic fatty liver disease trial by completing the investigator meeting. The three-arm, 60-patient clinical trial is assessing the effect of namodenoson on liver triglyceride concentrations. Release

> Paion raised €8 million ($9 million) in a private placement. The German specialty pharma company plans to use the money to prepare for a European phase 3 trial of remimazolam in general anesthesia. Statement

> BrainStorm Cell Therapeutics enlisted Massachusetts General Hospital and California Pacific Medical Center to enroll patients in a phase 3 trial of its amyotrophic lateral sclerosis candidate. Release